Litcius/Paper detail

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O’Malley

2023Gynecologic Oncology108 citationsDOI

Topics & Concepts

MedicineBevacizumabInternal medicineOvarian cancerGastroenterologyRegimenOncologyNauseaAdverse effectCancerSurgeryChemotherapyOvarian cancer diagnosis and treatmentHER2/EGFR in Cancer ResearchPARP inhibition in cancer therapy
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer | Litcius